Design of bifunctional antibiotics that target bacterial rRNA and inhibit resistance-causing enzymes [11]

Journal of the American Chemical Society

Volumn 122, Issue 21, 2000, Pages 5230-5231

  Sucheck, Steven J ^a   Wong, Andrew L ^a   Koeller, Kathryn M ^a   Boehr, David D ^b   Draker, Kari Ann ^b   Sears, Pamela ^a   Wright, Gerard D ^b   Wong, Chi Huey ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BACTERIAL RNA; NEAMINE; RIBOSOME RNA;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; BINDING KINETICS; DISSOCIATION CONSTANT; DRUG DESIGN; DRUG SYNTHESIS; ENZYME INHIBITION; LETTER; RNA BINDING; STOICHIOMETRY; SURFACE PLASMON RESONANCE;

EID: 0034738144     PISSN: 00027863     EISSN: None     Source Type: Journal    
DOI: 10.1021/ja000575w     Document Type: Letter

References (25)

1. Edson, R. S.; Terrel, C. L. Mayo Clin. Proc. 1991, 66, 1158.
2. (a) Moazed, D.; Noller, H. F. Nature 1987, 327, 389.
3. (b) Purohit, P.; Stem, S. Nature 1994, 370, 659.
4. (c) Formy, D.; Recht, M. I.; Blanchard, S. C.; Puglisi, J. D. Science 1996, 274, 1367.
5. (a) Wright, G. D.; Berghuis, A. M.; Mobashery, S. Adv. Exp. Med. Biol. 1998, 456, 27.
6. (b) Kondo, S.; Hotta, K. J. Infect. Chemother. 1999, 5, 1.
7. (c) Mingeot-Leclerco, M.-P.; Glupczynski, Y.; Tulkens, P. M. Antimicrob. Agents Chemother. 1999, 43, 727.
8. (a) Daigle, D. M.; Hughes, D. W.; Wright, G. D. Chem. Biol. 1999, 6, 99.
9. (b) Azucena, E.; Grapsas, I.; Mobashery, S. J. Am. Chem. Soc. 1997, 119, 2317.
10. (c) Patterson, J.-E.; Zervos, M. J. Rev. Infect. Dis. 1990, 12, 644.
11. (a) Recht, M. I.; Fourmy, D.; Blanchard, S. C.; Dahlquist, K. D.; Puglisi, J. D. J. Mol. Biol. 1996, 262, 421.
12. (b) Miyaguchi, H.; Narita, H.; Sakamoto, K.; Yokoyama, S. Nucleic Acids Res. 1996, 24, 3700.
13. (c) Hendrix, M.; Priestley, E. S.; Joyce, G. F.; Wong, C.-H. J. Am. Chem. Soc. 1997, 119, 3641.
14. (d) Wong, C.-H.; Hendrix, M.; Priestley, E. S.; Greenberg, W. A. Chem. Biol. 1998, 5, 397.
15. (e) Greenberg, W. A.; Priestley, E. S.; Sears, P. S.; Alper, P. B.; Rosenbohm, C.; Hendrix, M.; Hung, S.-C.; Wong, C.-H. J. Am. Chem. Soc. 1999, 121, 6527.
16. Hendrix, M.; Alper, P. B.; Priestley, E. S.; Wong, C.-H. Angew. Chem., Int. Ed. Engl. 1997, 36, 95.
17. Some aminoglycoside dimers were prepared previously; however, the monomoers bind the A-site stoichiometrically, see: Michael, K.; Wang, H.; Tor, Y. Bioorg. Med. Chem. 1999, 7, 1361. For vancomycin dimers, see: Rao, J.; Whitesides, G. H. J. Am. Chem. Soc. 1997, 119, 10286. Sundram, U. N.; Griffin, J. H.; Nicas, T. I. J. Am. Chem. Soc. 1996, 118, 13107.
18. Some aminoglycoside dimers were prepared previously; however, the monomoers bind the A-site stoichiometrically, see: Michael, K.; Wang, H.; Tor, Y. Bioorg. Med. Chem. 1999, 7, 1361. For vancomycin dimers, see: Rao, J.; Whitesides, G. H. J. Am. Chem. Soc. 1997, 119, 10286. Sundram, U. N.; Griffin, J. H.; Nicas, T. I. J. Am. Chem. Soc. 1996, 118, 13107.
19. Some aminoglycoside dimers were prepared previously; however, the monomoers bind the A-site stoichiometrically, see: Michael, K.; Wang, H.; Tor, Y. Bioorg. Med. Chem. 1999, 7, 1361. For vancomycin dimers, see: Rao, J.; Whitesides, G. H. J. Am. Chem. Soc. 1997, 119, 10286. Sundram, U. N.; Griffin, J. H.; Nicas, T. I. J. Am. Chem. Soc. 1996, 118, 13107.
20. Sucheck, S. J.; Greenberg, W. A.; Tolbert, T. J.; Wong, C.-H. Angew. Chem., Int. Ed. 2000, 39, 1080.
21. Phillips, I.; Williams, D. In Laboratory Methods in Antimicrobial Chemotherapy; Gerrod, L., Ed.; Churchill Livingstone Press: Edinburg, 1978; pp 3-30.
22. (a) Baldwin, J. J.; McClure, D. E.; Gross, D. M.; Williams, M. J. Med. Chem. 1982, 25, 931.
23. (b) Schlecker, R.; Thieme, P. C. Tetrahedron 1988, 44, 13289.
24. Devinsky, F.; Lacko, I.; Krasnec, L. Synthesis 1980, 4, 303.
25. Compound 27 is also effective against other strains, including Pseudomonas aeruginosa ATCC 27853, P. aeruginosa, PAO-1, S. aureus ATCC 29213 and ATCC 33591-MRSA, and Enterococcus faecalis ATCC 29212 and is 3 times more effective than tobramycin against the tobramycin-resistant strain of P. aeruginosa from cystic fibrosis patients.